Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Invested Capital (2020 - 2025)

Historic Invested Capital for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $292.0 million.

  • Mirum Pharmaceuticals' Invested Capital rose 2586.89% to $292.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $292.0 million, marking a year-over-year increase of 2586.89%. This contributed to the annual value of $225.6 million for FY2024, which is 926.13% down from last year.
  • Mirum Pharmaceuticals' Invested Capital amounted to $292.0 million in Q3 2025, which was up 2586.89% from $255.2 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Invested Capital's 5-year high stood at $292.0 million during Q3 2025, with a 5-year trough of $57.2 million in Q3 2021.
  • Moreover, its 5-year median value for Invested Capital was $171.1 million (2022), whereas its average is $178.4 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Invested Capital plummeted by 5239.87% in 2021, and later soared by 19883.3% in 2022.
  • Quarter analysis of 5 years shows Mirum Pharmaceuticals' Invested Capital stood at $122.2 million in 2021, then grew by 17.12% to $143.1 million in 2022, then skyrocketed by 73.74% to $248.7 million in 2023, then dropped by 9.26% to $225.6 million in 2024, then grew by 29.43% to $292.0 million in 2025.
  • Its last three reported values are $292.0 million in Q3 2025, $255.2 million for Q2 2025, and $233.3 million during Q1 2025.